Jaspaul (Paul) Singh’s Post

NMD Pharma A/S breaks new ground in neuromuscular diseases and Sophion Bioscience‘s instruments were part of their research from the start. From early on, Sophion’s #AutomatedPatchClamp instruments have been an important part of NMD Pharma’s research and data package. “The whole platform that Sophion offers can help you understand channel function better, cheaper and faster than if you had to do it another way – you get the whole package with Sophion,” says Martin Broch-Lips, Head of Biological Research at NMD Pharma A/S. Read the full 𝗡𝗠𝗗 𝗣𝗵𝗮𝗿𝗺𝗮 𝗰𝘂𝘀𝘁𝗼𝗺𝗲𝗿 𝗰𝗮𝘀𝗲 𝘀𝘁𝗼𝗿𝘆 here: https://lnkd.in/dp2MGSGu With an NMD670 orphan drug designation and achievement of a Phase IIa study in patients with myasthenia gravis, NMD Pharma has developed into a clinical stage biotech company focused on discovering and delivering life-transforming therapies for people living with neuromuscular diseases. #NMDPharma #QPatchCompact #PatchClamp #AutomatedPatchClamp #IonChannels #DrugDiscovery #Electrophysiology #Sophion

BioVie Inc. (NASDAQ:BIVI) said new preclinical data characterizing its lead drug candidate NE3107’s mechanism in action is being presented at the 2023 International Congress of Parkinson’s Disease and Movement Disorders (MDS) being held in Copenhagen, Denmark from August 27 to 31. BioVie CEO Cuong Do said that the results and analysis presented at the MDS this week added to the growing body of data for NE3107 that supports the company’s core understanding of this molecule and its potential in diseases such as Parkinson’s Disease (PD). “The presentations include new pre-clinical data that support the relationship between neuroinflammation and insulin resistance in diseases like PD, and new analyses from our Phase 2a clinical trial that further characterize the pharmacokinetics of NE3107 and its potential as an adjunctive or first-line therapy,” Do said. More at #Proactive #ProactiveInvestors #NASDAQ #BIVI http://ow.ly/TgxY104SrTa

Gene&Cell Therapy >> Merck's big ADC move; Latest from #ESMO23; How Eli Lilly is thinking about deals; AI-designed drugs face reckoning in clinic; and more: Welcome back to Endpoints Weekly, your review of the week’s top biopharma headlines. Want this in your inbox every Saturday morning? Current Endpoints readers can visit their reader profile to add Endpoints Weekly. New to Endpoints? Sign up here. As Reynald Castañeda, Kyle LaHucik and Lei Lei Wu bring us the latest ESMO news out of Madrid, don’t forget to sign up for our virtual event on Monday to get the experts’ take on where cancer research is now and where we are headed next. Merck’s big ADC move Merck is committing $4 billion upfront to team up with Daiichi Sankyo on a trio of antibody-drug conjugates, adding fuel to a space that’s heating up on blockbuster revenue, data readouts and a flurry of M&A. For Merck, it’s a way to “make sure we blanketed the field with the same intensity” that the company did with Keytruda, chief medical officer Eliav Barr told Endpoints. The most advanced program is slated for a BLA filing in 2024 and appears to have big potential in lung cancer, according to a trial investigator. Latest from #ESMO23 A broken embargo on the highest-profile abstracts at this year’s European Society for Medical Oncology forced the conference organizer to release data from the presentations several days early. Here’s our breakdown of the biggest datasets to watch. In one of the first presentations, Amgen detailed Phase II data for its bispecific tarlatamab in small cell lung cancer, Reynald Castañeda reports. How Eli Lilly is thinking about deals Eli Lilly is on a hot streak. Ahead of some big FDA decisions, Kyle LaHucik spoke with Lilly’s multi-hyphenated executive Dan Skovronsky about the company’s M&A plans, playing the long game in drug development and why it doesn’t need mega deals. Speaking of dealmaking, Kyle also reported that the company has agreed to acquire an antibody-drug conjugate biotech, swooping in for France-based Mablink Bioscience. AI-designed drugs face reckoning in clinic After years of hype, the first AI-designed drugs are falling short in the clinic. But executives at these first-generation companies say it’s too early for a verdict on whether or not AI boosts the odds of success, particularly given the vast likelihood that any drug candidate — AI-developed or not — will fail, Andrew Dunn writes. Q&A with Joe Jimenez Former Novartis CEO Joe Jimenez and his research right-hand, Mark Fishman, are testing a new approach to biotech investing and drug development Aditum Bio. In an interview with Kyle LaHucik, Jimenez talks about salvaging “stuck” drugs, biotech formation and why a substance abuse treatment could be worth billions of dollars. WHAT WE’RE WATCHING NEXT WEEK * Multiple major drugmakers will be reporting their… #lucidquest #genetherapy #celltherapy

LucidQuest Strategic Insights (lqventures.com) >>> Gene&Cell Therapy >> Merck's big ADC move; Latest from #ESMO23; How Eli Lilly is thinking about deals; AI-designed drugs face reckoning in clinic; and more: Welcome back to Endpoints Weekly, your review of the week’s top biopharma headlines. Want this in your inbox every Saturday morning? Current Endpoints readers can visit their reader profile to add Endpoints Weekly. New to Endpoints? Sign up here. As Reynald Castañeda, Kyle LaHucik and Lei Lei Wu bring us the latest ESMO news out of Madrid, don’t forget to sign up for our virtual event on Monday to get the experts’ take on where cancer research is now and where we are headed next. Merck’s big ADC move Merck is committing $4 billion upfront to team up with Daiichi Sankyo on a trio of antibody-drug conjugates, adding fuel to a space that’s heating up on blockbuster revenue, data readouts and a flurry of M&A. For Merck, it’s a way to “make sure we blanketed the field with the same intensity” that the company did with Keytruda, chief medical officer Eliav Barr told Endpoints. The most advanced program is slated for a BLA filing in 2024 and appears to have big potential in lung cancer, according to a trial investigator. Latest from #ESMO23 A broken embargo on the highest-profile abstracts at this year’s European Society for Medical Oncology forced the conference organizer to release data from the presentations several days early. Here’s our breakdown of the biggest datasets to watch. In one of the first presentations, Amgen detailed Phase II data for its bispecific tarlatamab in small cell lung cancer, Reynald Castañeda reports. How Eli Lilly is thinking about deals Eli Lilly is on a hot streak. Ahead of some big FDA decisions, Kyle LaHucik spoke with Lilly’s multi-hyphenated executive Dan Skovronsky about the company’s M&A plans, playing the long game in drug development and why it doesn’t need mega deals. Speaking of dealmaking, Kyle also reported that the company has agreed to acquire an antibody-drug conjugate biotech, swooping in for France-based Mablink Bioscience. AI-designed drugs face reckoning in clinic After years of hype, the first AI-designed drugs are falling short in the clinic. But executives at these first-generation companies say it’s too early for a verdict on whether or not AI boosts the odds of success, particularly given the vast likelihood that any drug candidate — AI-developed or not — will fail, Andrew Dunn writes. Q&A with Joe Jimenez Former Novartis CEO Joe Jimenez and his research right-hand, Mark Fishman, are testing a new approach to biotech investing and drug development Aditum Bio. In an interview with Kyle LaHucik, Jimenez talks about salvaging “stuck” drugs, biotech formation and why a substance abuse treatment could be worth billions of dollars. WHAT WE’RE WATCHING NEXT WEEK * Multiple… #lucidquest #genetherapy #celltherapy

Physiogenex will be presenting the effects of resmetirom (the first drug to be FDA approved for MASH) in its 3-week MASH mouse model at APASL 2024 Kyoto in Japan this week: moderated poster presentation on March 28th at 5:10-5:16pm Check out our model data here: https://lnkd.in/e4s5nMwz As a CRO running #MASH animal models for more than a decade, Physiogenex is very happy to see Resmetirom FDA approved for MASH patients without cirrhosis. This major event also opens new paths for other therapies to be approved for treatment of MASH and liver fibrosis. If you are developing these kinds of therapies and want to gain time and money to reach the clinics asap, we have the right preclinical model for you 🙂 ! Let's meet at APASL 2024 this week or contact us on our website: https://lnkd.in/eR8rpD7H We have a >20-year expertise in drug development and a 97.5% customer satisfaction rate over the last 3 years. Our expertise – your success   #MASH #drugdiscovery #preclinicalresearch

NMD Pharma will participate in the 28th International Annual Congress of the World Muscle Society, taking place in Charleston, SC from 3-7 October.   As one of the largest global meetings dedicated to research and understanding of neuromuscular pathology and diseases, we look forward to hearing about the latest developments in the field and sharing important clinical results of our exciting new approaches to helping patients regain their muscle strength and avoid the fatigue that affects many aspects of their daily lives.   Poster Session 4 – Myasthenia Gravis, Ballroom A/C 15:30–16:30 Friday October 6: P272: NMD670, a novel first-in-class muscle ClC-1 inhibitor, improves symptoms of Myasthenia Gravis: a randomized, single-dose, double-blind, placebo-controlled study. Quiroz J(1), Ruijs T(2),(3), S. Grønnebæk T(1), de Cuba K(2),(3), Heuberger J(2), de Kam M2 , Koopmans I(2),(3), de Goede A2, Tannemaat M(3), Vershuuren J(3), Bold J(1), Jensen K(1), Flagstad P(1), Petersen T(1), Chin E(1), Hutchison J(1), Groeneveld G(2),(3), Pedersen T(1). 1: NMD Pharma 2: Centre for Human Drug Research 3: Leiden University Medical Centre   For more: https://lnkd.in/gd7CfQSR   #WMS2023 #NMDPharma #Biotech #NeuromuscularDisease #MyastheniaGravis #SpinalMuscularAtrophy #CharcotMarieToothDisease #RareDisease

LucidQuest Strategic Insights (lqventures.com) >>> Gene&Cell Therapy >> Apellis expects EU to reject eye drug; Terray teams up with Bristol Myers; Vandria raises $20M: Plus, news on Inductive Bio, AbelZeta Pharma, GPCR Therapeutics, Bridge Biotherapeutics and NextCure. Apellis preempts EU rejection for eye drug: The company expects a negative opinion from the Committee for Medicinal Products for Human Use on pegcetacoplan, which is under review for the treatment of geographic atrophy secondary to age-related macular degeneration. The complement C5 inhibitor in February won US approval for the indication as Syfovre, but its launch has been plagued by real-world safety events. Apellis shares $APLS were down 20% on Thursday morning. — Ayisha Sharma Terray Therapeutics is partnering with Bristol Myers Squibb in a new drug discovery and development deal that aims to identify small molecules targeting “certain disease areas.” Financial terms of the deal, which includes an upfront and potential milestones, were not disclosed. — Jaimy Lee Swiss biotech debuts with $20.6M fundraise: Vandria plans to use the Series A proceeds to advance its portfolio of small molecule mitophagy inducers, including lead asset and central nervous system drug VNA-318. Mitophagy involves the selective removal and replacement of damaged mitochondria with anti-inflammatory effects. VNA-318 is set to enter the clinic in the second quarter of next year. — Ayisha Sharma Inductive Bio emerges from stealth: The startup’s $4.3 million seed round was led by Andreessen Horowitz Bio + Health and Lux Capital. Other investors include Character, Bessemer Venture Partners and Alleycorp. The company, which was founded by a pair of former Flatiron Health employees, is using machine learning to help chemists optimize compounds in the drug discovery process. — Jaimy Lee AbelZeta Pharma updated its licensing deal with Johnson & Johnson, which now has the option to get exclusive commercialization rights in China to two of the biopharma’s CAR-T treatment candidates. Both are being tested in patients with non-Hodgkin lymphoma. — Jaimy Lee GPCR Therapeutics, a Seoul-based biopharma, inked an out-licensing deal with Bridge Biotherapeutics for its CXCR4-LPA1 inhibitor combo. Bridge is paying $1.5 million upfront. — Jaimy Lee NextCure, a Maryland biopharma developing immunotherapies, is “actively” seeking partners to further progress its programs. — Jaimy Lee #lucidquest #genetherapy #celltherapy

We are pleased to share that our B2i Digital featured portfolio company, Unicycive Therapeutics (NASDAQ: $UNCY), will present two posters related to their lead candidate, Oxylanthanum Carbonate (OLC), at the upcoming National Kidney Foundation meeting in May. As noted in Unicycive’s release (https://lnkd.in/eyxbcw6t), new data will be featured from OLC’s bioequivalence study establishing pharmacodynamic equivalence to the approved drug Fosrenol. Survey results on factors impacting patient compliance with existing phosphate binders will also be presented. CEO Shalabh Gupta, MD commented, “We are proud to present two posters related to OLC at the National Kidney Foundation Spring Clinical Meeting, one of the premier medical conferences for the healthcare community focused on kidney disease. Importantly, we will present new data from the bioequivalence study for OLC. We will also present results of a survey conducted to understand why patients may be non-compliant in taking the currently prescribed phosphate binders. We look forward to contributing meaningful results to this important event.” We commend the Unicycive team, including EVP Pramod Gupta, Dr. Guru Reddy, and EVP Doug Jermasek, on sharing valuable scientific insights that help address the immense daily pill burden dialysis patients currently face in managing hyperphosphatemia. We proudly include Unicycive as a B2i Digital Featured Company, representing our commitment to spotlighting leaders in healthcare innovation. To learn more about Unicycive, please visit their IR website at https://ir.unicycive.com/ We look forward to their continued progress. To see Unicycive's full B2i Digital Featured Company Profile, visit https://lnkd.in/eg9U-h4f #biotech #medtech #leadership #patientimpact #raredisease #kidneydisease #innovation #pharmainnovation #B2iDigital #Unicycive

Gene&Cell Therapy >> Apellis expects EU to reject eye drug; Terray teams up with Bristol Myers; Vandria raises $20M: Plus, news on Inductive Bio, AbelZeta Pharma, GPCR Therapeutics, Bridge Biotherapeutics and NextCure. Apellis preempts EU rejection for eye drug: The company expects a negative opinion from the Committee for Medicinal Products for Human Use on pegcetacoplan, which is under review for the treatment of geographic atrophy secondary to age-related macular degeneration. The complement C5 inhibitor in February won US approval for the indication as Syfovre, but its launch has been plagued by real-world safety events. Apellis shares $APLS were down 20% on Thursday morning. — Ayisha Sharma Terray Therapeutics is partnering with Bristol Myers Squibb in a new drug discovery and development deal that aims to identify small molecules targeting “certain disease areas.” Financial terms of the deal, which includes an upfront and potential milestones, were not disclosed. — Jaimy Lee Swiss biotech debuts with $20.6M fundraise: Vandria plans to use the Series A proceeds to advance its portfolio of small molecule mitophagy inducers, including lead asset and central nervous system drug VNA-318. Mitophagy involves the selective removal and replacement of damaged mitochondria with anti-inflammatory effects. VNA-318 is set to enter the clinic in the second quarter of next year. — Ayisha Sharma Inductive Bio emerges from stealth: The startup’s $4.3 million seed round was led by Andreessen Horowitz Bio + Health and Lux Capital. Other investors include Character, Bessemer Venture Partners and Alleycorp. The company, which was founded by a pair of former Flatiron Health employees, is using machine learning to help chemists optimize compounds in the drug discovery process. — Jaimy Lee AbelZeta Pharma updated its licensing deal with Johnson & Johnson, which now has the option to get exclusive commercialization rights in China to two of the biopharma’s CAR-T treatment candidates. Both are being tested in patients with non-Hodgkin lymphoma. — Jaimy Lee GPCR Therapeutics, a Seoul-based biopharma, inked an out-licensing deal with Bridge Biotherapeutics for its CXCR4-LPA1 inhibitor combo. Bridge is paying $1.5 million upfront. — Jaimy Lee NextCure, a Maryland biopharma developing immunotherapies, is “actively” seeking partners to further progress its programs. — Jaimy Lee #lucidquest #genetherapy #celltherapy